Researchers at Cardiff University have identified urolithin A, a metabolite produced by gut bacteria from pomegranate polyphenols, as a potential therapeutic agent to reduce vascular inflammation and stabilize atherosclerotic plaques. While traditional cardiovascular treatments focus on lowering cholesterol, this compound targets the underlying inflammatory processes of atherosclerosis, offering a potential complementary approach to existing therapies, according to Professor Dipak Ramji, Professor of Cardiovascular Science at the institution.
How does urolithin A affect heart health?
Urolithin A works by mitigating the biological drivers of plaque formation within artery walls. According to research led by Professor Dipak Ramji at Cardiff University, the compound significantly reduces oxidative stress and inflammatory signaling in vascular cells. In preclinical studies using mice, the team observed that urolithin A supplementation resulted in smaller, more stable plaques with a reduced risk of rupture. Unlike statins, which primarily target lipid levels, urolithin A addresses the immune and inflammatory pathways that contribute to residual cardiovascular risk in patients who have already achieved target cholesterol levels.
Why does the gut microbiome influence cardiovascular outcomes?
The health benefits of pomegranate consumption are not uniform across the population because they depend on the gut microbiome’s ability to convert plant-based compounds into active metabolites. As Professor Ramji explains, ellagitannins found in pomegranates—such as punicalagin—are poorly absorbed by the body on their own. They must be processed by specific gut microbes into urolithins, including urolithin A. Because this microbial capacity varies between individuals, some people may derive significant cardiovascular benefits from these foods while others may not, highlighting the importance of precision nutrition.
What are the challenges for clinical development?
Translating urolithin A into a standardized therapy involves significant regulatory and clinical hurdles. While phase I human trials for other indications have shown the compound is safe and well-tolerated at doses up to 1,000 mg per day, it has not yet been tested in dedicated cardiovascular outcome trials. Professor Ramji notes that future research must address patient variability, optimize dosing, and confirm the compound’s ability to reverse established plaques in human subjects. Despite these challenges, the compound’s favorable bioavailability and synthetic accessibility make it a more viable candidate for drug development than many other naturally derived nutraceuticals.
Frequently Asked Questions
- Can eating pomegranates replace my heart medication? No. Professor Ramji emphasizes that urolithin A is being investigated as a potential complementary therapy to work alongside existing treatments like statins, not as a replacement.
- Does everyone get the same benefit from pomegranate juice? Likely not. The ability to produce urolithin A depends on your specific gut microbiota, which explains why dietary outcomes can vary between individuals.
- When will this be available as a drug? Clinical cardiovascular trials are not yet underway. Professor Ramji estimates that early-phase clinical studies could be achievable within the next few years.
Are you interested in how the microbiome impacts long-term health? Subscribe to our newsletter for the latest updates on precision nutrition and cardiovascular research, or explore our archives for more on emerging therapeutic developments.
